NCT01840293Recruiting
Breast Cancer Proteomics and Molecular Heterogeneity
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: * To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1780 (estimated)
- First submitted
- 23 Apr 2013
- Start date
- 1 Feb 2013
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Cancer Trials Ireland
- Diseases
- Metastatic breast cancer
- NCT number
- NCT01840293
What you commit to
- Study type: Observational
- Planned participants: 1780
- From 1 Feb 2013 to the primary completion date, 31 Dec 2029
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue
- Or
- -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection/biopsy and/or treatment of tumour tissue
- Or
- -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection/biopsy and/or treatment of their tumour tissue
- Patients receiving neoadjuvant treatment are also eligible (if applicable)
- Patients have to be ≥ 18 years of age
- Patients must be able to give informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cork University Hospital Coordinator of this site? Confirm its status | Cork | Ireland | Recruiting |
| St Vincent's University Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Recruiting |
| St. James's Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Completed |
| Beaumont Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Recruiting |
| University Hospital Limerick Coordinator of this site? Confirm its status | Limerick | Ireland | Active, not recruiting |
| University Hospital Waterford Coordinator of this site? Confirm its status | Waterford | Ireland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.